Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats.
Francesco DiMeco; Khan W Li; Berry M Tyler; Ariel S Wolf; Henry Brem; Alessandro Olivi (Profiled Authors: Betty Tyler; Francesco Dimeco; Henry Brem; Alessandro Olivi)
Department of Neurosurgery, Istituto Nazionale Neurologico C. Besta, Milan, Italy.
Journal of neurosurgery 2002;97(5):1173-8.
OBJECT: Mitoxantrone is a drug with potent in vitro activity against malignant brain tumor cell lines; however, its effectiveness as a systemic agent has been hampered by poor central nervous system penetration and dose-limiting myelosuppression. To avoid these problems, we incorporated mitoxantrone into biodegradable polymeric wafers to be used for intracranial implantation, a strategy that has been shown to be safe and successful in the treatment of malignant gliomas. The authors investigated the release kinetics, toxicity, distribution, and efficacy of mitoxantrone delivered from intracranially implanted biodegradable wafers in the treatment of 9L gliosarcoma in Fischer 344 rats. METHODS: Mitoxantrone released from the biodegradable wafer matrix reached therapeutic drug concentrations in the brain for at least 35 days. Only animals with implanted wafers of the highest drug loading dose (20% mitoxantrone by weight) showed signs of significant toxicity. In three separate efficacy experiments, animals treated with mitoxantrone-loaded biodegradable wafers had significantly improved survival compared with control animals. The combined median survival for each treatment group was the following: 0% mitoxantrone wafers, 19 days; 1%, 30 days, p < 0.0001; 5%, 34 days, p < 0.0001; and 10%, 50 days, p < 0.0001. CONCLUSIONS: These findings establish that mitoxantrone delivered from intracranially implanted biodegradable wafers is effective in the treatment of malignant gliomas in rodents and should be considered for future clinical application in humans.
Scientific Context
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Related Publications
-
1.
1993R J Tamargo; J S Myseros; J I Epstein; M B Yang; M Chasin; H Brem
Cancer research 1993;53(2):329-33. -
2.
2002Phillip B Storm; John L Moriarity; Betty Tyler; Peter C Burger; Henry Brem; Jon Weingart
Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy.
Journal of neuro-oncology 2002;56(3):209-17. -
3.
2003Laurence D Rhines; Prakash Sampath; Francesco DiMeco; H Christopher Lawson; Betty M Tyler; Justin Hanes; Alessandro Olivi; Henry Brem
Neurosurgery 2003;52(4):872-9; discussion 879-80.
Related Topics
Appears in this Publication
Related Experts
Author of this Publication
-
Internal ExpertsPublications
-
212









-
78









-
54









-
112









-
73









-
420










